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I NCREASING focus is being placed on enhanced recov-ery after surgery (ERAS) protocols for various major 
surgical procedures aiming to speed up recovery and reduce 
the length of hospital stay (LOS).1,2 One of the cornerstones 
of ERAS protocols is perioperative fluid management with 
avoidance of salt and water overload.2 In a previous random-
ized trial, we have shown that a simple hydration protocol 
focusing on a zero postoperative fluid balance significantly 
reduces overall major complications and gastrointestinal 
(GI) complications by more than 50%.3,4
GI recovery is a critical factor determining postoperative 
recovery and consequently LOS. Electrolyte disturbances can 
negatively impact GI function, especially low potassium and 
magnesium levels. A relevant number of patients receiving a 
balanced physiologic crystalloid solution (Ringer’s maleate) 
perioperatively experience serum electrolyte disturbances in 
the early postoperative period after cystectomy and urinary 
diversion and need substitution. Excessive administration of 
normal saline (NaCl, 0.9%) is associated with higher GI and 
renal complication rates compared to balanced solutions.4–6 
Thus, optimization of perioperatively administered crystal-
loid solutions is required.
What We Already Know about This Topic
•	 Delayed	 return	of	gastrointestinal	 function	often	complicates	
radical	cystectomy
•	 A	potassium-enriched,	chloride-depleted	5%	glucose	solution	
may	accelerate	recovery	of	gastrointestinal	function
•	 The	authors	randomized	44	patients	to	the	chloride-depleted	
solution	or	Ringer's	maleate	solution
What This Article Tells Us That Is New
•	 The	primary	outcome,	 time	 to	 first	defecation,	did	not	differ	
significantly
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ABSTRACT
Background: Gastrointestinal (GI) complications often delay recovery after radical cystectomy with urinary diversion. The 
authors investigated if perioperative administration of a potassium-enriched, chloride-depleted 5% glucose solution (G5K) 
accelerates recovery of GI function.
Methods: This randomized, parallel-group, single-center double-blind trial included 44 consecutive patients undergoing radi-
cal cystectomy and pelvic lymph node dissection with urinary diversion. Patients were randomized to receive either a G5K 
(G5K group) solution or a Ringer’s maleate solution (control group). Fluid management aimed for a zero fluid balance. 
Primary endpoint was time to first defecation. Secondary endpoints were time to normal GI function, need for electrolyte 
substitution, and renal dysfunction.
Results: Time to first defecation was not significantly different between groups (G5K group, 93 h [19 to 168 h] and control 
group, 120 h [43 to 241 h]); estimator of the group difference, −16 (95% CI, −38 to 6); P = 0.173. Return of normal GI func-
tion occurred faster in the G5K group than in the control group (median, 138 h [range, 54 to 262 h] vs. 169 h [108 to 318 h]); 
estimator of the group difference, −38 (95% CI, −74 to −12); P = 0.004. Potassium and magnesium were less frequently sub-
stituted in the G5K group (13.6 vs. 54.5% [P = 0.010] and 18.2 vs. 77.3% [P < 0.001]), respectively. The incidence of renal 
dysfunction (Risk, Injury, Failure, Loss and End-stage kidney disease stage “risk”) at discharge was 9.1% in the G5K group 
and 4.5% in the control group; P = 1.000.
Conclusions: Perioperative administration of a G5K did not enhance first defecation, but may accelerate recovery of 
normal GI function, and reduces potassium and magnesium substitution after radical cystectomy and urinary diversion. 
(A nesthesiology 2016; XXX:00-00)
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Crystalloids and Postoperative Bowel Function
Open radical cystectomy combined with pelvic lymph 
node dissection and urinary diversion was chosen as a major 
surgery model for this study because it is an extensive and 
time-consuming, but standardized, surgical intervention in 
a high-caseload tertiary center. In addition, despite improve-
ments in surgical technique and perioperative care, radical 
cystectomy is associated with early postoperative complica-
tion rates of more than 50% and a 90-day mortality rate of 
2 to 7%.3,7
We hypothesized that the perioperative administration of 
a novel potassium-enriched, chloride-depleted 5% glucose 
solution (G5K) improves GI recovery while reducing elec-
trolyte disturbances when compared to a balanced Ringer’s 
maleate solution.
Material and Methods
Ethics
The study was approved by the local ethics committee 
(Kantonale Ethikkommission Bern, Bern, Switzerland; 
KEKBE 151/13) and by the Swiss Agency for Therapeutic 
Products, Bern, Switzerland (2014DR4097). It was pro-
spectively registered at http://www.controlled-trials.com 
(ISRCTN32976792; principal investigator: Dr. Wuethrich; 
date of registration: October 30, 2013) and conducted in 
compliance with the Declaration of Helsinki and Good 
Clinical Practice. All patients gave previous written informed 
consent.
Study Design and Patients
This is a prospective, randomized, parallel-group, asses-
sor- and patient-blinded, high-caseload, single-center inter-
ventional superiority trial conducted at the Department of 
Urology, University Hospital Bern, Bern, Switzerland.
Consecutive patients presenting for open radical cystectomy, 
pelvic lymph node dissection, and urinary diversion (ileal con-
duit, orthotopic bladder substitute, continent catheterizable 
ileal reservoir) were screened for eligibility and recruited from 
July 2014 to May 2015. Inclusion criteria were age more than 
or equal to 18yr and American Society of Anesthesiologists’ 
physical status II or III. Exclusion criteria were pregnancy, con-
gestive heart failure (New York Heart Association classification 
more than or equal to 3), severe hepatic disease, and estimated 
glomerular filtration rate less than 45 ml/min.
Patients were prospectively randomized 1:1 by a com-
puter-generated list with 11 blocks of 4 patients. The ran-
dom allocation sequence was implemented by a study 
coordinator blinded to the study codes and was generated by 
the hospital pharmacy. Patients were enrolled by the research 
coordinator or the senior surgeon. Patients were included in 
strict numerical order and assigned to the group mentioned 
in the sealed, nontransparent envelope with the correspond-
ing number. The similar-looking infusion bags were specially 
prepared and provided by the hospital pharmacy in accor-
dance with good manufacturing practice. The investigators 
who assessed the return of GI function and performed the 
statistical analysis were blinded to the randomization.
Perioperative Management
Preoperatively, no antegrade bowel preparation was admin-
istered, but two high enemas were given the evening before 
surgery. Patients had oral intake till midnight before surgery 
and were encouraged to drink clear fluid till 2 h before anes-
thesia induction.
Surgery was performed in a standardized fashion as previ-
ously described with the patient in a 30° head-down position 
and with one of three senior urologists present.8–10 A gas-
trostomy tube was placed intraoperatively, and the orogastric 
tube was removed at the end of the procedure. The ureteral 
stents were exteriorized.
In the intervention group (G5K group), patients received 
a potassium-enriched, chloride-depleted 5% glucose crystal-
loid solution (G5K solution, Bichsel, Switzerland) and in the 
control group, a balanced Ringer’s maleate solution (Ring-
erfundin®, B. Braun, Switzerland) as a baseline infusion 
during the entire period requiring intravenous fluid admin-
istration. The main differences in electrolyte concentrations 
between the two solutions (G5K vs. Ringerfundin®) were as 
follows: chloride (65.0 vs. 127.0 mmol/l), sodium (50.0 vs. 
145.0 mmol/l), potassium (30.0 vs. 4.0 mmol/l), and mag-
nesium (2.0 vs. 1.0 mmol/l) concentrations. The G5K solu-
tion contained in addition 50 g/l glucose (277.4 mmol/l), 
lactate 18.0 mmol/l, and phosphate 8.0 mmol/l (table 1).
Intraoperatively, the assigned solution was administered 
at a rate of 1 ml kg−1 h−1 until the bladder was removed, 
followed by 3 ml kg−1 h−1 until the end of surgery. Norepi-
nephrine was titrated as needed from 2 to 8 μg kg−1 h−1 
to maintain a mean arterial pressure of 60 to 100 mmHg. 
If this was not sufficient to correct hypotension less than 
Table 1. Electrolyte Composition of the Two Different 
Crystalloid Solutions
G5K Group  
(G5K Solution)
Control Group  
(Ringerfundin®)
Sodium (mmol/l) 50.0 145.0
Potassium (mmol/l) 30.0 4.0
Magnesium (mmol/l) 2.0 1.0
Calcium (mmol/l) 0 2.5
Hydrogen (from hydrochloric 
acid) (mmol/l)
15.0 0
Chloride (mmol/l) 50.0 127.0
Chloride (from hydrochloric 
acid) (mmol/l)
15.0 0
Acetate (mmol/l) 0 24.0
Maleate (mmol/l) 0 5.0
Lactate (mmol/l) 18.0 0
Hydrogen phosphate (mmol/l) 8.0 0
Glucose (g/l) 50 (i.e., 277.4 
mmol/l)
0
Osmolality (mOsm/kg) 454 309
G5K = potassium-enriched, chloride-depleted 5% glucose solution.
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60 mmHg, boluses of 250 ml of Ringer’s maleate solution 
were infused in both groups. Blood loss exceeding 500 ml 
was compensated with an equal amount of Ringer’s male-
ate solution. Packed erythrocytes were transfused if hemo-
globin values dropped less than 80 g/l (less than 100 g/l in 
patients with coronary artery disease). If hypotension per-
sisted or if severe metabolic acidosis (base excess less than 
−5, pH less than 7.25) caused by hypovolemia occurred, 
additional boluses of Ringer’s maleate solution were given in 
both groups. Patients with one to two risk factors for postop-
erative nausea and vomiting (PONV) were prophylactically 
treated with antiemetics (ondansetron).
Postoperatively, patients received 1,500 ml of the crys-
talloid solution allocated by randomization per day until 
oral substitution was adequate. The crystalloid solutions 
were administered using a pump with limited volume per 
time because of the relatively high potassium concentra-
tion in the G5K solution. Patient management adhered to 
our standardized care pathway.11 Patients were allowed to 
drink clear fluids immediately after surgery, were encour-
aged to chew gum, and were started on an oral liquid diet 
on postoperative day (POD) 1. Subcutaneous 0.5 mg neo-
stigmine daily was administered from POD 2 on under 
cardiac monitoring. A gastrostomy tube was initially left 
on drainage at bed level, closed if patients were without 
nausea and vomiting for more than 24 h, and removed 
once patients passed stool. Antiemetic therapy (intra-
venous ondansetron and/or droperidol) was initiated if 
patients experienced PONV.
Electrolyte substitution was performed according to our 
internal guideline in case of hypokalemia (K+ less than 3.5 
mmol/l), hypomagnesemia (Mg++ less than 0.66 mmol/l; 
both with intravenous substitution), and moderate hypo-
natremia (Na+ less than 130 mmol/l; oral substitution). In 
case of hyperglycemia (more than 10 mmol/l), patients were 
treated with subcutaneous insulin injection (4 IU).
Bedside mobilization was encouraged as soon as possible, 
ideally the evening after surgery, or not later than the next 
morning. Active ambulation, including exercising in bed, 
sitting out of bed, and standing and walking in the room 
was started on POD 1, and prolonged mobilization as well 
as sitting in a chair were started on POD 2. Epidural anal-
gesia remained until POD 5 combined with an opioid-free 
systemic analgesia (paracetamol and metamizol).
Endpoints
Primary endpoint was the time from end of surgery until 
first defecation (first portion of feces). Secondary endpoints 
were time to first flatus and normal GI function defined as 
defecation of a portion of normal stool (Bristol form scale 3 
to 4).12As first defecation is the most widely used endpoint 
in GI recovery, we based our power analysis on this. How-
ever, we additionally considered the defecation of a normal 
portion of stool as a relevant secondary endpoint (i.e., return 
of normal GI function), as first defecation can be defecation 
of residual stool (i.e., rectal emptying in case of no preop-
erative bowel preparation) due to stimulation or paradoxical 
diarrhea.13 This endpoint was added after registration but 
before recruitment of the first patient.
Patients were instructed to report the occurrence of flatus 
and defecation, which was recorded twice daily by the study 
nurse. Stool consistency and odor were also assessed by the 
ward nurse and documented by a study nurse. Bodyweight 
was measured every morning at the same time. Postoperative 
ileus (POI) was defined as no return of bowel function after 
POD 6 requiring cessation of oral intake, intravenous sup-
port, or nasogastric tube placement.14 Incidence of PONV 
and antiemetic use were recorded.15
In addition, postoperative fluid balance (i.e., difference 
in bodyweight) and event of renal dysfunction according 
to the Acute Kidney Injury Network and Risk, Injury, Fail-
ure, Loss and End-stage kidney disease classifications were 
assessed.16–18
Safety endpoints included measurement of biochemi-
cal parameters (sodium, potassium, chloride, magnesium, 
hydrogen phosphate, osmolality, brain natriuretic peptide, 
renin, and aldosterone), urine electrolytes (sodium, chlo-
ride), and osmolality during the first 4 PODs.19 Plasma and 
urine samples were collected every morning at the same time 
(5:00 AM). Dyselectrolytemia was defined as hyperchloremia 
(plasma value more than 107 mmol/l), hypo- or hyperka-
lemia (more than 4.5 or less than 3.5 mmol/l), hyponatre-
mia (less than 135 mmol/l), or hypomagnesemia (less than 
0.66 mmol/l). Perioperative normoglycemia was defined as 
glucose plasma levels between 4.5 and 10.0 mmol/l. Hypoos-
molality was defined as lower than 280 mOsm/kg.
Statistical Analysis
Based on internal retrospective data in a similar surgical 
population (time until first defecation, 4.82 days; SD, of 
0.82 day), we calculated that a sample size of 18 patients per 
arm randomized 1:1 would have a 90% power (β = 0.10) 
to detect a difference of 1 day between the groups at a two-
sided significance level of 5% (α = 0.05) assuming a SD of 
1 day. Presuming a drop-out rate of 20%, 22 patients per 
group were recruited.
Statistical analyses were conducted on an intention-to-
treat basis. Data are expressed in medians with ranges for 
continuous variables or frequencies for categorical ones. Cat-
egorical data were compared with the Fisher exact or the chi-
square test and continuous data with the Mann–Whitney U 
test for comparison of the two independent groups because 
of small sample sizes. Group differences in the primary out-
come were evaluated using the Mann–Whitney U test for 
two independent groups. Nonparametric 95% CIs with 
Hodges–Lehmann (HL) estimator were used for differences 
of the two group medians.
A two-sided P < 0.05 was considered significant. Statisti-
cal analysis was performed by the Institute of Mathematical 
Statistics and Actuarial Science, University of Bern (Bern, 
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Switzerland) using the Statistical Analysis System software 
(version 9.3; SAS Institute, USA).
Results
Demographics
Of 53 consecutive patients, 44 fulfilled the eligibility crite-
ria, were randomized, and had complete follow-up data for 
the final analysis (fig. 1). Baseline demographic characteris-
tics did not differ significantly between the groups (table 2).
Intraoperative and Postoperative Procedures
There was no statistically significant difference between 
groups regarding surgical characteristics, LOS, intraoperative 
parameters, and fluid administration (G5K group: 750 ml 
[range, 500 to 1,700 ml] vs. control group 975 ml [400 to 
1,600 ml]; P = 0.185). The amount of fluid administered 
postoperatively (G5K group: 4,750 ml [4,000 to 6,000 ml] 
vs. control group 5,250 ml [4,000 to 6,000 ml], P = 0.941) 
and fluid balance did not differ significantly between the 
groups during the first 4 PODs. There was a significant dif-
ference in the salt load administered between the two groups 
(table 3).
Bowel Function
Time to first flatus did not differ significantly between 
groups: G5K group (44 h [13 to 118 h]) and control group 
(50 h [22 to 114 h]); HL estimator of the group difference, 
−2.5 (95% CI, −22 to 13); P = 0.716. Time to first defeca-
tion did not differ significantly between groups: G5K group 
(93 h [19 to 168 h]) and control group (120 h [43 to 241 h]); 
HL estimator of the group difference, −16 (95% CI, −38 to 
6); P = 0.173. Time to return of normal GI function was 
significantly shorter in the G5K group (138 h [54 to 262 h]) 
than in the control group (169 h [108 to 318 h]); HL esti-
mator of the group difference, −38 (95% CI, −74 to −12); 
P = 0.004 (fig. 2).
There was no significant difference in the incidence and 
duration of POI between groups: G5K 4.5% (1/22 patients), 
3 days, and control 9.1% (2/22 patients), 3 and 4 days; 
P = 1.000. The incidence of at least one episode of PONV 
during PODs 1 to 4 was 22.7% (5/22 patients) in the G5K 
group and 45.5% (10/22) in the control group; P = 0.203. 
All patients with episodes of PONV received antiemetics 
(intravenous ondansetron and droperidol).
Estimated Renal function, Dyselectrolytemia, and 
Glycemia
There was no significant difference in median plasma creati-
nine values and estimated glomerular filtration rate between 
the groups postoperatively. Median potassium and magne-
sium plasma values were significantly lower in the control 
group on PODs 3 and 4 even if a Bonferroni correction 
for multiple testing (6 time points) of these components is 
applied. Median sodium plasma values were significantly 
lower in the G5K group on PODs 3 and 4, and median 
sodium urine value was significantly lower on POD 4 even if 
a Bonferroni correction for multiple testing (6 time points) 
of this component is applied. Median chloride plasma values 
were significantly lower in the G5K group.
Fig. 1. Consort flowchart diagram. G5K = potassium-enriched, chloride-depleted 5% glucose solution.
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Urinary sodium values were significantly lower in the 
G5K group 6 h after surgery and on POD 4 even if a Bon-
ferroni correction for multiple testing (6 time points) of 
these components is applied. Urine chloride values were 
only significantly lower in the G5K group 6 h after surgery. 
Urine osmolality did not differ significantly between groups 
(table 4).
The rates of potassium and magnesium intravenous sub-
stitution were significantly higher in the control (54.5 and 
77.3%) than in the G5K (13.6 and 18.2%) group, P = 0.010 
and P < 0.001, respectively. There was no difference between 
groups for any of the renal dysfunction classifications (table 5).
At least 1 episode of mild hyponatremia was present in 
13 of 22 patients (59.1%) in the G5K group and in 4 of 
22 patients (18.2%) in the control group; P = 0.012 (table 
5). However, overall only five patients in the G5K and one 
in the control group had a sodium plasma value under 134 
mmol/l from POD 1 to 4.
Plasma glucose values were similar between the two 
groups (table 4). Episodes of hyperglycemia were present in 
3 of 22 patients (13.6%) in the G5K group (measured 6 h 
after surgery, treated with a single subcutaneous injection of 
4 IU insulin per patient) and in 6 of 22 patients (27.3%) in 
the control group (measured 6 h after surgery [4 IU insulin 
per patient] and on POD 1 [4 IU insulin per patient]).
Complications
The in-hospital complication rate did not differ between 
groups with the exception of a higher rate of surgical com-
plications in the control group (31.8%: 2 lymphoceles, 4 
wound dehiscences, and 1 ureteral anastomotic leak) com-
pared to the G5K group (4.5%: 1 lymphocele); P = 0.046 
(table 5).
In addition, we found four patients (18.2%) with neuro-
logic complications in the G5K group (one transient isch-
emic attack on POD 2 due to a preoperatively not diagnosed 
internal carotid artery stenosis and three transient senso-
motoric dysfunctions of the obturator nerve after surgical 
lymph node dissection). In the control group, we found two 
patients (9.1%) with neurologic complications (one tran-
sient confusion on POD 1 [with normal plasma sodium 
level at this time point] and one sensomotoric lesion of the 
femoral nerve due to positioning).
Discussion
We were unable to detect a statistically significant differ-
ence in the time from end of surgery until first defecation 
(first portion of feces), our primary endpoint. However, a 
relevant finding of this prospective randomized study is that 
the return of normal GI function (secondary endpoint) was 
accelerated by perioperative administration of a potassium-
enriched, chloride-depleted 5% glucose crystalloid as a 
perioperative maintenance solution when compared to the 
usually used balanced crystalloids. In addition, the need for 
postoperative intravenous potassium and magnesium sub-
stitution was reduced in the G5K group, suggesting fewer 
perioperative electrolyte shifts in this group.
There is some evidence that the quantity of crystalloid 
solution administered perioperatively influences postopera-
tive rehabilitation and morbidity as well as having an impact 
on postoperative recovery.4,5,20 A positive salt and water bal-
ance delay return of GI function in patients undergoing 
Table 2. Baseline Demographics and Surgical Patient 
Characteristics
Characteristics
G5K  
Group  
(n = 22)
Control  
Group  
(n = 22)
Age (yr) 71.5 (33.0–82.0) 63.5 (47.0–77.0)
Body weight (kg) 72.3 (42.0–90.0) 76.1 (52.0–173.0)
Height (cm) 170 (153–181) 172 (156–194)
BMI (kg/m2) 24.7 (17.9–31.1) 25.8 (17.9–45.9)
Gender (female/male) 6/16 (27/73) 8/14 (36/64)
ASA physical status score
  II 13 (59) 15 (68)
  III 9 (41) 7 (32)
Glasgow Prognostic Score
  0 8 (36) 10 (46)
  1 or 2 14 (64) 12 (55)
Ischemic heart disease 3 (14) 4 (18)
Hypertension 11 (50) 9 (41)
Diabetes mellitus type II 0 (0) 2 (9)
COPD 6 (27) 2 (9)
CKD
  CKD grade 1 5 (23) 6 (27)
  CKD grade 2 (mild) 17 (77) 12 (55)
  CKD grade 3 (moderate) 0 (0) 4 (18)
Aspirin 2 (9) 4 (18)
Antihypertensives 9 (41) 8 (36)
Statins 4 (18) 4 (18)
β-Blocking agents 3 (14) 1 (5)
Neoadjuvant chemotherapy 6 (27) 6 (27)
Type of cancer
  Urothelial carcinoma 19 (86) 18 (82)
  Leiomyosarcoma 1 (5) 1 (5)
  Squamous cell carcinoma 2 (9) 3 (14)
Tumor stage (pT)
  Tis/CIS 1 (5) 1 (5)
  Ta 4 (18) 5 (22)
  T1 1 (5) 1 (5)
  T2 2 (9) 7 (32)
  T3 10 (46) 6 (27)
  T4 4 (18) 2 (9)
Nodal involvement stage
  pN 0 16 (73) 17 (77)
  pN + 6 (27) 5 (23)
Metastasis
  M0 21 (96) 21 (96)
  M1 0 (0) 1 (5)
  M2 1 (5) 0 (0)
Data are presented as median (range) or absolute value (%).
ASA = American Society of Anesthesiologists; BMI = body mass index; 
CIS = carcinoma in situ; CKD = chronic kidney disease; COPD = chronic 
obstructive pulmonary disease; G5K = potassium-enriched, chloride-
depleted 5% glucose solution; Tis = tumor in situ.
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colorectal surgery or cystectomy,4–6 while patients with no 
weight gain on POD 1 have fewer overall and GI compli-
cations.5,6 However, not only the quantity of crystalloid 
solution but also the type of electrolytes in the crystalloid 
solution infused is of relevance. Normal saline solution (i.e., 
0.9% NaCl), still the most commonly used crystalloid solu-
tion worldwide, contains excessive amounts of chloride and 
sodium. Administration of large amounts of saline solution 
has been associated with increased postoperative morbid-
ity compared to more physiologic balanced crystalloids.21 
Saline solution overload results in metabolic acidosis, with 
decreased renal blood flow, renal dysfunction, prolonged GI 
recovery time, and increased infectious complication rates 
compared to balanced crystalloid solutions.6,21–24
After having demonstrated, in the context of an ERAS 
protocol,2 that a fluid management scheme based on a zero 
postoperative weight gain dramatically reduces complica-
tions and LOS, we now compared a balanced Ringer’s male-
ate solution to a novel potassium-enriched (30 mmol/l) and 
chloride-depleted (65 mmol/l) 5% glucose–based crystalloid 
solution.4 Both groups had a similar fluid balance of around 
zero (i.e., no weight gain postoperatively) as a prerequisite 
according to our previously published protocol.4 Using 
the novel solution, return of GI function was significantly 
reduced by more than 1 day; this is relevant and comparable 
to the published outcomes in other studies, which focused 
on optimizing postoperative GI function.25 The substantially 
higher sodium and chloride load in the control group but 
similar urinary sodium and chloride concentrations postop-
eratively when compared to the G5K group suggest a rel-
evant sodium and chloride retention in the control group. 
This is possibly explained by the kidneys’ limited ability to 
excrete water and electrolytes perioperatively as a response 
to surgical trauma and postoperative stress reaction.24 The 
observed difference in perioperative electrolyte load could be 
an explanation for the delayed return of GI function and 
the nonsignificant trend toward a longer time to first fla-
tus and defecation in the control group. Both hypokalemia, 
which occurred in the control group, and hyponatremia 
caused by fluid overload have been reported to be risk fac-
tors for delayed return of normal GI function and POI26,27 
by impairing intrinsic small bowel myogenic and neurogenic 
Table 3. Perioperative Management
Characteristics
G5K Group  
(n = 22)
Control Group  
(n = 22) P Value
Estimator  
of Group  
Differences 95% CI
Type of urinary derivation
  Ileal OBS 10 (46) 13 (59) 0.667
  Ileal conduit 11 (50) 7 (32)
  Continent ileal reservoir 1 (5) 2 (9)
Surgery duration (min) 373 (210 to 540) 397 (230 to 480) 0.731 10.0 −30 to 58
Blood loss (ml) 880 (200 to 1,800) 1,200 (200 to 2,200) 0.135 200.0 −90 to 600
Intraoperative fluid and salt administered
  Crystalloid according to randomization (ml) 750 (500 to 1,700) 975 (400 to 1,600) 0.185 100.0 −50 to 300
  Total intravenous sodium (mmol) 161 (25 to 274) 283 (102 to 471) < 0.001 134.0 74.8 to 199.8
  Total intravenous chloride (mmol) 108 (65 to 191) 248 (89 to 413) 0.002 99.5 43.4 to 189.8
  Total intravenous potassium (mmol) 26 (15 to 56) 8 (3 to 13) < 0.001 −18.3 −22.6 to −15.2
  Total intravenous magnesium (mmol) 3 (1 to 5) 2 (1 to 3) 0.09 −0.4 −0.9 to 0.05
  Additional Ringerfundin® (ml) 850 (0 to 1,500) 1,000 (0 to 2,250) 0.135 250.0 0 to 700
  Packed erythrocytes (n) 3 (14) 3 (14) 1.000
  FFP (n) 2 (9) 1 (5) 1.000
  Fluid balance on POD 1 0.20 (−1.50 to 2.20) 0.75 (−1.60 to 2.70) 0.137 0.6 −0.2 to 1.4
Postoperative fluid administered
  Crystalloid according to randomization (ml) 4,750 (4,000 to 6,000) 5,250 (4,000 to 6,000) 0.941 0.0 0 to 0
  Packed erythrocytes (ml) 0 (0 to 500) 0 (0 to 500) 0.755 1.0 0 to 0
  Number of patients with packed erythrocytes (n) 7 (32) 9 (41) 0.754
  Packed erythrocytes administered (n) 14 (64) 16 (73)
  Fluid balance on POD 1 0.20 (−1.50 to 2.20) 0.75 (−1.60 to 2.70) 0.137 0.6 −0.2 to 1.4
  Fluid balance on POD 2 0.05 (−1.10 to 2.00) −0.05 (−2.90 to 1.50) 0.326 −0.1 −0.7 to 0.5
  Fluid balance on POD 3 0.20 (−1.00 to 1.80) −0.20 (−2.20 to 1.90) 0.342 −0.2 −0.7 to 0.3
  Fluid balance on POD 4 −0.40 (−2.50 to 2.00) −0.50 (−2.50 to 2.00) 0.589 0.6 −0.1 to 1.2
  Total intravenous sodium (mmol) 238 (200 to 300) 761 (580 to 870) < 0.001 512.5 380 to 570
  Total intravenous chloride (mmol) 309 (260 to 390) 667 (508 to 762) < 0.001 357.3 248 to 372
  Total intravenous potassium (mmol) 143 (120 to 180) 21 (16 to 24) < 0.001 −122.5 −156 to −104
  Total intravenous magnesium (mmol) 10 (8 to 12) 5 (4 to 6) < 0.001 −4.3 −6 to −4
Data are presented as median (range) or absolute value (%). Estimator of the group differences: Hodges–Lehmann estimator of the differences of the group 
medians, with corresponding 95% CI.
FFP = fresh frozen plasma; G5K = potassium-enriched, chloride-depleted 5% glucose solution; OBS = orthotopic bladder substitution; POD = postoperative day.
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activity. Although patients in the G5K group had lower 
sodium plasma values and a higher incidence of mild hypo-
natremia, osmolality and fluid balance did not differ from 
the control group. This suggests a compensated fluid load 
and possibly explains why mild hyponatremia did not affect 
GI recovery. The higher incidence of mild hyponatremia in 
Fig. 2. Return of gastrointestinal (GI) function. Data are presented as box plots with whiskers as minimum and maximum values 
and interquartile range (box). G5K = potassium-enriched, chloride-depleted 5% glucose solution.
Copyright © 2016, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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the G5K group had no apparent adverse effect, and it was 
not associated with fluid retention. It is likely that impaired 
GI function recovery as a consequence of hyponatremia, 
which has been reported by some studies, is more likely 
caused by the concomitant fluid overload than by the hypo-
natremia per se.
Magnesium is another factor potentially affecting recov-
ery of GI function.28 As the G5K solution contains two-
fold more magnesium than the balanced Ringer’s maleate 
solution (Ringerfundin®) and patients in the control group 
required significantly more magnesium replacement postop-
eratively, this could be another factor favoring return of GI 
function in the G5K group.
Intracellular uptake of glucose (50 g/l in the G5K solu-
tion) and at the same time by uptake of water through osmo-
sis probably results in a less pronounced interstitial edema in 
the GI tract. Due to the 5% glucose content and low sodium 
and chloride concentration, the G5K solution is more likely 
to shift water from intravascular to interstitial to intracel-
lular, than a similar quantity of balanced Ringer’s maleate 
solution would (i.e., intravascular to interstitial). Interstitial 
edema, due to fluid overload or inadequate crystalloid choice 
(saline solution), is another factor known to affect GI func-
tion and cause prolonged POI.29–31
The goal of an intravenous maintenance solution is to 
substitute the daily needs for water and electrolytes and 
Table 5. Side Effects and In-hospital Complications
G5K Group  
(n = 22)
Control Group 
(n = 22) P Value
Electrolytes/biochemistry
  BNP plasma value (> 100 pg/ml) 8 (36.4) 11 (50.0) 0.543
  Hypophosphatemia (< 0.8 mmol/l) 6 (27.3) 10 (45.5) 0.348
  Hyperchloremia (> 107 mmol/l) 12 (54.5) 18 (81.8) 0.104
  Hypokalemia (< 3.5 mmol/l) 2 (9.1) 4 (18.2) 0.664
  Hyperglycemia (> 10.0 mmol/l) 3 (13.6) 6 (27.3) 0.457
  Hypoosmolality (< 280 mmol/l) 10 (45.5) 9 (40.9) 1.000
  Hyponatremia (< 135 mmol/l) 13 (59.1) 4 (18.2) 0.012
Mild hyponatremia (130–134 mmol/l)
  6 h postoperatively 11 (50) 6 (27.3)
  POD 1 8 (36.4) 3 (13.6)
  POD 2 3 (13.6) 0 (0)
  POD 3 3 (13.6) 1 (4.5)
  POD 4 4 (18.2) 0 (0)
Moderate hyponatremia (< 130 mmol/l)
  6 h postoperatively 1 (4.5) 0 (0)
  POD 1 1 (4.5) 0 (0)
  POD 2 1 (4.5) 0 (0)
  POD 3 1 (4.5) 0 (0)
  POD 4 1 (4.5) 0 (0)
Hypomagnesemia (< 0.66 mmol/l) 8 (36.4) 14 (63.6) 0.131
Hyperaldosteronism (> 340 pmol/l) 9 (40.9) 9 (40.9) 1.000
Increased renin plasma value 19 (86.4) 20 (90.9) 1.000
Electrolyte replacement
Patients with intravenous potassium replacement 3 (13.6) 12 (54.5) 0.010
Patients with intravenous magnesium replacement 4 (18.2) 17 (77.3) < 0.001
Patients with subcutaneous insulin injection 3 (13.6) 6 (27.3) 0.457
Total amount of insulin injected (IU) 12 24
Patients with sodium replacement (oral) 2 (9.1) 0 0.488
Criteria for kidney injury
  Transient AKIN (stage1/2) POD 1–2 1/1 (9.1) 0 (0) 0.488
  RIFLE at discharge (class R “risk”) 2 (9.1) 1 (4.5) 1.000
Number of patients developing at least one complication (n) 13 (59.1) 9 (40.9) 0.366
Cardiovascular complications (n) 5 (22.7) 2 (9.1) 0.412
Pulmonary complications (n) 3 (13.6) 3 (13.6) 1.000
Infectious complications (n) 2 (9.1) 5 (22.7) 0.412
Surgical complications (n) 1 (4.5) 7 (31.8) 0.046
Neurologic complications (n) 4 (18.2) 2 (9.1) 0.664
Length of hospital stay (d) 14.5 (10–23) 15.5 (11–26) 0.233
Data are presented as n (%) or as median (range).
AKIN = Acute Kidney Injury Network; BNP = brain natriuretic peptide; G5K = potassium-enriched, chloride-depleted 5% glucose solution; POD = postop-
erative day; RIFLE = Risk, Injury, Failure, Loss and End-stage kidney disease.
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to reduce ketosis starvation by giving 50 to 100 g glucose, 
1 mmol kg−1 d−1 potassium, and 1mmol kg−1 d−1 sodium.32 
These requirements are better met by the G5K crystalloid 
solution than the balanced Ringer’s maleate solution, a solu-
tion containing no glucose and substantially less potassium. 
Therefore, it is not surprising that patients in the control 
group needed significantly more potassium substitution 
and had statistically but not clinically relevant higher chlo-
ride and sodium plasma values. This is an important find-
ing, as hypokalemia is another factor known to impair GI 
recovery.33
Established postoperative strategies to accelerate return of 
GI function and reduce POI have already been established 
in patients undergoing radical cystectomy with urinary 
diversion: use of epidural analgesia to avoid opioid use, alvi-
mopan administration, chewing gum, and early oral intake 
are examples.15,25 The amount of perioperative fluid and 
the electrolytes substituted is considered another key ele-
ment, albeit still controversial. This study suggests that the 
electrolyte composition of a balanced crystalloid solutions 
influences the return of normal GI function. This is a more 
objective parameter than the commonly used first defeca-
tion, as the latter may be influenced by neostigmine, sup-
positories, or enemas or only reflect rectal emptying.
This study has some limitations. Many factors impact 
GI function such as the surgery (open vs. minimally inva-
sive, type of urinary derivation, extent of pelvic lymph node 
dissection, bowel segment selected, blood loss, duration of 
surgery), anesthesiologic factors (opioids, fluid overload), 
and individual risks (gender, age, comorbidities, Glasgow 
prognostic score).34 However, surgical and anesthesiologic 
bias was limited in our study, as perioperative management 
adhered to the same center-specific pathways in all patients. 
In addition, this study was performed in a high–caseload 
center; thus, it remains unclear if these findings can be 
extrapolated to other centers and larger patient populations. 
Finally, this study was not powered to confidently assess 
safety. However, we could not detect a difference in in-hos-
pital complications including neurologic disturbances asso-
ciated with dyselectrolytemia (i.e., acute changes in sodium 
plasma level and its correction). It has to be emphasized 
that the G5K solution, mainly because of its relatively high 
potassium concentration, should only be administered as a 
maintenance fluid using a volumetric pump.
Conclusion
The administration of a potassium-enriched, chloride-
depleted 5% glucose crystalloid as a perioperative main-
tenance solution in conjunction with a zero perioperative 
fluid balance did not significantly affect the time to first 
defecation (primary endpoint), but accelerated the return of 
normal GI function (secondary endpoint) after open radi-
cal cystectomy and urinary diversion. It reduced the post-
operative need for potassium and magnesium substitution. 
However, this potassium-enriched, chloride-depleted 5% 
glucose crystalloid solution resulted in substantial postop-
erative mild hyponatremia mandating close monitoring of 
plasma sodium.
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